Plus   Neg

Stock Alert: Aurinia Pharma Jumps 11% On Priority Review For Voclosporin

Shares of Aurinia Pharmaceuticals Inc. (AUPH) are gaining about 11% on the Nasdaq. The other day, the U.S. Food and Drug Administration accepted the filing of the company's New Drug Application for voclosporin, a potential treatment for lupus nephritis.

AUPH is currently trading at $16.00, up $1.52 or 10.50%, on the Nasdaq.

The FDA has granted priority review for the NDA, which provides an expedited six month review, and has assigned a Prescription Drug User Fee Act target action date of January 22, 2021.

Lupus nephritis is a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus.

"People living with LN are in need of an advanced therapy that quickly drives the disease into remission and mediates kidney damage," said Peter Greenleaf, President and Chief Executive Officer of Aurinia. "We will continue to collaborate with the FDA during their review process and in parallel build our commercial readiness for a potential approval and commercial launch in the first quarter of 2021."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Macy's is offering a sneak peek of its Black Friday deals for this year, so that shoppers can get a head start on finding some of the best deals. The department store has unveiled its Black Friday deals that will be available next month across categories, including fashion, fine jewelry, tech, beauty, toys and home specials. Some of the deals will be available for as low as $5. Italy's antitrust watchdog has opened an investigation against Google for an alleged abuse of dominant position in the Italian market for display advertising. This refers to the space publishers and website owners make available for the display of advertising content. Shares of Deutsche Bank AG were gaining around 3 percent in German trading after the banking major reported Wednesday a profit in its third quarter, compared to prior year's loss mainly driven by strong Investment Bank revenues. Looking ahead, the bank said it remains on track to meet all financial and strategic targets related to its transformation plan.
Follow RTT